Corcept's 31.7% YoY revenue surge in 2026Q2 to $256.1M, driven by its lead product Korlym, underscores robust commercial execution and a fortress balance sheet (D/E of 0.01).
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 31.7% YoY in 2026Q2, with gross margin holding at 98.4%, though SG&A escalation (up 88% since 2024Q4) compressed operating margin to 16.1%.
The March 2026 approval of ROSELLA transitioned it from a trial story to a launch story, bolstering confidence in its potential as a significant ovarian-cancer franchise.
Corcept retains a profitable base business with 2026 revenue guidance of $900-$1,000 million and holds $532.4 million in cash, cash equivalents, and marketable securities.
Despite risks, the relacorilant NDA represents a key growth driver, with its approval potentially driving significant upside for the company.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 3, 2026 | $1.01+20.2% vs $0.84 | $340M+0.4% vs $339M |
Q3 2026 Jul 29, 2026 | $0.36+1383.3% vs $0.02 | $256M+15.8% vs $221M |
Q2 2026 Apr 30, 2026 | -$0.30-172.3% vs -$0.11 | $165M-11.0% vs $185M |
Q1 2026 Feb 24, 2026 | $0.20-39.4% vs $0.33 | $202M-20.7% vs $255M |
Corcept Therapeutics Incorporated (NASDAQ: CORT - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eight ratings firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating
Corcept's Q3 earnings and revenues beat estimates, driven by strong Lifyorli uptake and higher Korlym sales, as the company advances its pipeline.
Corcept Therapeutics Incorporated (CORT) Q3 2026 Earnings Call Transcript
Corcept Therapeutics NASDAQ: CORT reported third-quarter 2026 revenue of $340.5 million, up 33% from the prior quarter and 64% from a year earlier, as growth in its endocrinology business and the launch of ovarian cancer treatment Lifyorli lifted results.
Benchmark CORT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Corcept Therapeutics Incorporated (CORT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $72.77 | $7.81B | 55.34 | 12.79% | 16.81% | 22.94% | — | |
| $19.10 | $1.41B | 7.12 | 18.52% | 43.79% | 15.84% | — | |
| $33.11 | $1.92B | 11.06 | 21.51% | 18.05% | 18.55% | — | |
| $26.16 | $3.19B | 7.09 | 4.29% | 32.75% | — | — | |
| $15.85 | $2.19B | -1.25 | -2.75% | -43.27% | -68.13% | 7.26% | |
| $32.96 | $1.34B | 13.14 | 17.12% | 6.67% | 27.44% | 1.44% |
Corcept Therapeutics Incorporated (CORT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Corcept Therapeutics Incorporated (CORT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 29, 2026·SEC
Jun 17, 2026·SEC
Jun 3, 2026·SEC
Get notified when CORT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Corcept Therapeutics Incorporated (CORT) stock FAQ — growth, dividends, profitability & financials explained
Corcept Therapeutics Incorporated (CORT) reported $963.6M in revenue over the trailing twelve months. Revenue was $761.4M in fiscal year 2025.
Corcept Therapeutics Incorporated (CORT) grew revenue by 30.0% over the trailing twelve months, compared with the twelve months before.
Yes. Corcept Therapeutics Incorporated (CORT) earned $162.0M in net income over the trailing twelve months (a 16.8% net margin).
Corcept Therapeutics Incorporated (CORT) had a return on equity (ROE) of 22.9% over the trailing twelve months. That is well above the market's typical 10-15%.
Corcept Therapeutics Incorporated (CORT) generated $194.6M in free cash flow over the trailing twelve months.
